Business Wire

St. Jude Medical Announces CE Mark Approval for the HeartMate 3 Left Ventricular Assist System

With approval, the HeartMate 3 System offers physicians in Europe the most advanced ventricular assist technology available to support the management of patients with advanced stage heart failure ST.
Business Wire

St. Jude Medical HeartMate 3 LVAS Demonstrated Improved Clinical Outcomes for Patients Suffering from Advanced Heart Failure

MOMENTUM 3 Study meets primary endpoint for short-term indication Results presented during late-breaking clinical trial session at the AHA Scientific Sessions MOMENTUM 3 Study data published in the ...
EurekAlert!

Patients on HeartMate 3 have fewer blood-related events than those on HeartMate II

A six-month analysis of the pivotal MOMENTUM 3 trial found that patients implanted with the new HeartMate 3 left ventricular assist system (LVAS) had fewer adverse clotting and bleeding events than ...
JD Supra

Abbott Obtains FDA Approval for HeartMate 3 Device

Abbott announced on October 19, 2018 that its HeartMate 3 Left Ventricular Assist Device (LVAD) has received U.S. Food and Drug Administration (FDA) approval as a destination therapy for people living ...
BioWorld

Heartmate 3 data may unravel LVAD riddle

Pump thrombosis has been such a well-established shortcoming of left ventricular assist devices (LVADs), that one heart surgeon went so far as to borrow Winston Churchill's phraseology to describe it ...
Medscape

FDA Clears HeartMate 3 Pump for HF Destination Therapy

The US Food and Drug Administration has approved the HeartMate 3 left ventricular assist system (Abbott) as a long-term destination therapy for patients with advanced heart failure who are ineligible ...